Literature DB >> 19550396

Tumor hypoxia and malignant progression.

S Osinsky1, M Zavelevich, P Vaupel.   

Abstract

The current problems of malignant growth biology, in particular the molecular background of the specific microenvironment of tumor cells and their interaction with stromal cells, which mediates the behavior of tumors and the tumor-host interrelationship were the subject of the International Conference entitled "Tumor Hypoxia and Malignant Progression", a meeting held at the House of Scientists of the NAS of Ukraine in Kyiv, Ukraine, October 1 st to 4 th , 2008. The meeting was hosted by the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine (IEPOR), and was dedicated to the 90 th Anniversary of the National Academy of Sciences of Ukraine. Over the last years, scientists have focused extensively on the problem of tumor hypoxia as a factor promoting tumor progression. It is known that hypoxia, as a constituent of the tumor cell microenvironment as well as aerobic glycolysis, are important features of malignant tumors. The direct correlation between high levels of hypoxia and tumor aggressiveness has been shown in numerous studies. Therefore, hypoxia is regarded as a factor of unfavorable prognosis. There is a number of different methods available for the evaluation of the level of hypoxia, some of which are being applied in the clinical setting. The stimulating impact of hypoxia and hypoxia-associated proteins on neoangiogenesis and vasculogenesis in tumor tissue has been demonstrated. Several studies have focused on the development of agents capable of blocking hypoxia-associated signaling pathways and vasculogenesis in tumor. Recently, the direct association between hypoxia-dependent signaling pathways and expression of factors that mediate inflammation in tumor tissue, in particular tumor-associated macrophages has been shown. To summarize, a better understanding of the relationships between hypoxia-associated signaling pathways, metabolic peculiarities and inflammatory factors that positively influence tumor progression may elucidate not only how the aggressive tumor phenotype is formed but also may assist in the development of new approaches for the treatment of cancer patients.

Entities:  

Mesh:

Year:  2009        PMID: 19550396

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  21 in total

1.  Molecular biology: the key to personalised treatment in radiation oncology?

Authors:  D G Hirst; T Robson
Journal:  Br J Radiol       Date:  2010-09       Impact factor: 3.039

2.  Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells.

Authors:  J Ciura; P P Jagodziński
Journal:  Mol Biol Rep       Date:  2010-03-07       Impact factor: 2.316

3.  High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.

Authors:  Raoul A Droeser; Uwe Güth; Serenella Eppenberger-Castori; Sylvia Stadlmann; Christian Hirt; Luigi Terracciano; Gad Singer
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-28       Impact factor: 4.553

Review 4.  Lipid rafts: integrated platforms for vascular organization offering therapeutic opportunities.

Authors:  Anna Laurenzana; Gabriella Fibbi; Anastasia Chillà; Giancarlo Margheri; Tommaso Del Rosso; Elisabetta Rovida; Mario Del Rosso; Francesca Margheri
Journal:  Cell Mol Life Sci       Date:  2015-01-01       Impact factor: 9.261

Review 5.  Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.

Authors:  Bingxue Shang; Zhifei Cao; Quansheng Zhou
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

6.  Regulation of matrix stiffness on the epithelial-mesenchymal transition of breast cancer cells under hypoxia environment.

Authors:  Yonggang Lv; Can Chen; Boyuan Zhao; Xiaomei Zhang
Journal:  Naturwissenschaften       Date:  2017-04-05

7.  Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs.

Authors:  Elodie Jouberton; Aurélien Voissiere; Frédérique Penault-Llorca; Florent Cachin; Elisabeth Miot-Noirault
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

8.  In vitro assay for single-cell characterization of impaired deformability in red blood cells under recurrent episodes of hypoxia.

Authors:  Yuhao Qiang; Jia Liu; Ming Dao; E Du
Journal:  Lab Chip       Date:  2021-09-14       Impact factor: 7.517

9.  Expression and clinical significance of glucose transporter-1 in pancreatic cancer.

Authors:  Kai Lu; Jian Yang; DE-Chun Li; Song-Bing He; Dong-Ming Zhu; Li-Feng Zhang; X U Zhang; Xiao-Chen Chen; Bing Zhang; Jian Zhou
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

10.  Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.

Authors:  Raoul Droeser; Inti Zlobec; Ergin Kilic; Uwe Güth; Michael Heberer; Giulio Spagnoli; Daniel Oertli; Coya Tapia
Journal:  BMC Cancer       Date:  2012-04-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.